| Class | Colloid fluid |
|---|---|
| Chemistry |
Concentrated human protein solution |
| Routes of administration |
IV |
| Absorption |
Zero oral bioavailability; degraded into component peptides by digestive enzymes |
| Solubility |
pKa 6.75; good water solubility |
| Distribution |
VOD = 0.07L/kg (effectively confined to the circulating volume); minimally protein bound |
| Metabolism |
Metabolised mainly by the reticuloendothelial system |
| Elimination |
Minimal renal excretion, except in cases of protein-losing nephropathy. Most of it is degraded by macrophages; 10% is eliminated though the gut |
| Time course of action |
Half life of around 27 days |
| Target receptor |
Various molecules in the bloodstream bind and form complexes |
| Mechanism of action |
Multiple roles, including oncotic, immunomodulatory and transport roles. Acts as a binding substrate for xenobiotics. |
| Clinical effects |
Increased circulating volume; may cause circulaotry overload; small risk of anaphylaxis or allergica reaction; may change the free fraction of highly protein-bound drugs
|
| Literature reference |
CSL Behring product sheet
|
| CICM details of understanding | Level 1 |
| Mentioned around Deranged Physiology |
Physiology and pharmacology of albumin, or broadly Physiology and pharmacology of colloid fluids, from which follows Response to 100ml of concentrated (20%) human albumin and The use of albumin in critical illness. Also Albumin in the body fluid compartments, a subtrope of Constituents and functions of plasma. Not to be confused with 4% Albumin (also see Osmotic pressure and oncotic pressure). |
| Related SAQs |
Question 9 from the first paper of 2022 Question 12 from the second paper of 2020 Question 1 from the second paper of 2015 Question 1(p.2) from the second paper of 2009 |